ArticleCureus2025
Efficacy and Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer and Autoimmune Diseases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cross-talk between aging resilience pathways and autoimmunity onset.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune diseases (AIDs) are often associated with lung cancer, but their clinical characteristics remain unclear. PURPOSE: The study aimed to elucidate the clinical features of non-small cell lung cancer (NSCLC) in patients with AIDs.
methodsThis single-center, retrospective observational study was conducted between June 2016 and October 2024. It included patients diagnosed with primary NSCLC and comorbid AIDs who received lung cancer treatment.
resultsA total of 32 patients (median age: 68 years; male/female: 14/18) were enrolled. Rheumatoid arthritis was the most common AID (10 cases, 31.3%), followed by Graves' disease, Hashimoto's thyroiditis, and ulcerative colitis (four cases each, 12.5%). Other AIDs included systemic lupus erythematosus (two cases, 6.3%) and one case (3.1%) each of Behçet's disease, dermatomyositis, myasthenia gravis, scleroderma, Schmidt's syndrome, psoriasis, and sarcoidosis. Immune checkpoint inhibitors (ICIs) were administered to 11 patients (34.3%), with a response rate and disease control rate of 63.6%. Immune-related adverse events (irAEs) occurred in 72.7% (8/11) of patients, including one grade 3 event. Of which, AID exacerbation related to ICI occurred in 45.5% (5/11) of patients. The median progression-free survival was 126 days, and the median overall survival (OS) was 1,594 days. Among patients without driver mutations who received ICI therapy, the median OS was significantly longer compared to those with driver mutations (2,274 vs. 654 days; P < 0.001). Multivariate analysis revealed that good performance status, adenocarcinoma history, and ICI administration were associated with better OS.
conclusionsICIs may be effective in selected NSCLC patients with AIDs; however, careful monitoring is essential due to the risk of irAE and AID exacerbation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.